Population study reports incidence and prevalence of CAAri in Northern Ireland, suggesting varied patient presentations.
Cerebral amyloid angiopathy-related inflammation (CAAri) can present with acute or subacute encephalopathy, focal neurologic deficits, or seizures. In a population study, we describe epidemiologic, clinical, and radiologic features of patients with CAAri. Using multiple sources, a cohort of patients diagnosed with CAAri in Northern Ireland was recruited over 12 years. Standardized incidence and prevalence data, clinical presentation, radiologic findings, treatment, and outcome were recorded. Twenty-five patients (12 women, 13 men) presented with CAAri (mean age 69.8 (SD 9.7) years). The age-standardized incidence of CAAri was 0.128 (95% CI 0.078-0.179)/100,000/y, and the point prevalence of CAAri was 0.904 (0.461-1.346)/100,000. Patients presented with subacute cognitive decline or behavioral change, focal deficits, headache, seizures, and falls. MRI contrast enhancement occurred in 5 of 17 (29%), and 19 of 25 (76%) had over 50 cerebral microbleeds. Nineteen patients (76%) were treated with steroid therapy ± other immunotherapies. Neuroimaging improvement occurred in most patients, but 7 patients (28%) had clinical progression. The median survival was 81 (95% CI 43.5-118.5) months. CAAri is rare and has a broad spectrum of presentations. Most patients with CAAri survive more than 6 years. Further research is required to identify the most appropriate immunotherapy regimen for patients with CAAri.
No takes yet. Share an insight, caveat, or question.
Todd et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: